FDx Advisors Inc. lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 94.3% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 520 shares of the company’s stock after selling 8,664 shares during the quarter. FDx Advisors Inc.’s holdings in Eli Lilly and Company were worth $471,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of LLY. AMJ Financial Wealth Management bought a new position in Eli Lilly and Company during the 4th quarter worth approximately $201,000. Providence First Trust Co bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $274,000. Aveo Capital Partners LLC lifted its holdings in shares of Eli Lilly and Company by 8.2% in the 4th quarter. Aveo Capital Partners LLC now owns 2,020 shares of the company’s stock worth $1,178,000 after purchasing an additional 153 shares during the last quarter. Gryphon Financial Partners LLC lifted its holdings in shares of Eli Lilly and Company by 19.4% in the 4th quarter. Gryphon Financial Partners LLC now owns 2,324 shares of the company’s stock worth $1,355,000 after purchasing an additional 377 shares during the last quarter. Finally, Bogart Wealth LLC lifted its holdings in shares of Eli Lilly and Company by 61.5% in the 4th quarter. Bogart Wealth LLC now owns 289 shares of the company’s stock worth $168,000 after purchasing an additional 110 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.
Insider Transactions at Eli Lilly and Company
In other news, major shareholder Lilly Endowment Inc sold 75,510 shares of Eli Lilly and Company stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $860.78, for a total value of $64,997,497.80. Following the transaction, the insider now directly owns 97,793,810 shares in the company, valued at $84,178,955,771.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders have sold 876,900 shares of company stock worth $788,605,032. Company insiders own 0.13% of the company’s stock.
Eli Lilly and Company Price Performance
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Analysts forecast that Eli Lilly and Company will post 16.51 EPS for the current fiscal year.
Eli Lilly and Company Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a $1.30 dividend. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.55%. Eli Lilly and Company’s payout ratio is presently 76.58%.
Wall Street Analyst Weigh In
LLY has been the topic of several recent research reports. JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $900.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th. Truist Financial reissued a “buy” rating and issued a $1,000.00 price target (up previously from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Guggenheim lifted their target price on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a research note on Monday, August 19th. Finally, BMO Capital Markets lifted their target price on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Two analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $961.76.
Read Our Latest Stock Report on Eli Lilly and Company
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Stories
- Five stocks we like better than Eli Lilly and Company
- Options Trading – Understanding Strike Price
- 3 ETFs to Build a Simple and Balanced Stock Portfolio
- What Does a Stock Split Mean?
- Charles Schwab’s Initiative Changes Are a Long-Term Positive
- Insider Buying Explained: What Investors Need to Know
- 3 Stocks to Watch as the Economy Shifts to the Cloud
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.